X-Rx is an early stage biotech company focused on the development of small molecule medicines in inflammation, fibrosis and oncology.
Founded in 2012 as a spin-out of X-Chem, X-Rx is an early stage biotech company with more than 80 years of combined drug discovery and development experience. Together and in partnership with a number of CROs, we focus on the creation of first and best in class, pre-clinical small molecule drug candidates. With access to the industry’s best DNA-encoded library screening platform, we are able to address difficult to drug targets, many of which are highly validated and offer first-in–class opportunities.
What makes us unique?
- A collection of high-value targets
- Access to the industry's best DNA-encoded library screening platform
- The ability to quickly identify tractable lead series on a wide range of targets including many that have been deemed undruggable